J&J Product Targeting Histamine H3 Receptor Moves Into Clinic

Johnson & Johnson is moving a drug candidate targeting the histamine H3 receptor into clinical development in half the time it has historically taken to advance a candidate, J&J Pharmaceuticals Group Worldwide Chairman William Weldon told an April 18 teleconference.